The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Elective and Onco-fertility preservation: factors related to IVF outcomes
Open accessAbstract
STUDY QUESTION: Is the indication for fertility preservation (FP) related to success in IVF cycles after elective-FP (EFP) for age-related fertility decline and FP before cancer treatment (Onco-FP)? SUMMARY ANSWER: Although success rates were lower in cancer patients, there was no statistically significant association between malignant disease and reproductive outcome after correction for age and controlled-ovarian stimulation (COS) regime. WHAT IS KNOWN ALREADY: FP is increasingly applied in assisted reproduction, but little is known about the outcome of IVF cycles with vitrified oocytes in FP patients. STUDY DESIGN, SIZE, DURATION: Retrospective, observational multicenter study of vitrification cycles for FP and of the warming cycles of women who returned to attempt pregnancy from January 2007 to May 2018. PARTICIPANTS/MATERIALS, SETTING, METHODS: In all, 6362 women (EFP = 5289 patients; 7044 cycles + Onco-FP = 1073 patients; 1172 cycles) had their oocytes vitrified for FP. A logistic regression analysis was performed to examine the impact of indication for FP corrected for age at vitrification. The protocol used for COS was also included as a possible confounder. The main outcome measures were oocyte survival and live birth. A detailed description of the baseline and clinical data is provided, with comparisons between EFP and Onco-FP. The cumulative live birth rate (CLBR) per utilized oocyte according to age at vitrification was analyzed in those patients returning to use their oocytes. MAIN RESULTS AND ROLE OF CHANCE: Age at vitrification was significantly older in EFP patients (37.2 ± 4.9 vs. 32.3 ± 3.5 year; P < 0.0001). Fewer oocytes were retrieved and vitrified per cycle in EFP (9.6 ± 8.4 vs. 11.4 ± 3.5 and 7.3 ± 11.3 vs. 8.7 ± 2.1, respectively; P < 0.05), but numbers became comparable when analyzed per patient (12.8 ± 7.4 vs. 12.5 ± 3.2 and 9.8 ± 6.4 vs. 9.5 ± 2.6). Storage time was shorter in EFP (2.1 ± 1.6 vs. 4.1 ± 0.9 years; P < 0.0001). In all, 641 (12.1%) EFP and 80 (7.4%) Onco-FP patients returned to attempt pregnancy (P < 0.05). Overall oocyte survival was comparable (83.9% vs. 81.8%; NS), but lower for onco-FP patients among younger (≤35 year) subjects (81.2% vs. 91.4%; P > 0.05). Fewer EFP cycles finished in embryo transfer (50.2% vs. 72.5%) (P < 0.05). The implantation rate was 42.6% and 32.5% in EFP versus Onco-FP (P < 0.05). Ongoing pregnancy (57.7% vs. 35.7%) and live birth rates (68.8% vs. 41.1%) were higher in EFP patients aged ≤35 than the Onco-FP matching age patients (P < 0.05). The reason for FP per se had no effect on oocyte survival (OR = 1.484 [95%CI = 0.876-2.252]; P = 0.202) or the CLBR (OR = 1.275 [95%CI = 0.711-2.284]; P = 0.414). Conversely, age (<36 vs. ≥36 y) impacted oocyte survival (adj.OR = 1.922 [95%CI = 1.274-2.900]; P = 0.025) and the CLBR (adj.OR= 3.106 [95%CI = 2.039-4.733]; P < 0.0001). The Kaplan-Meier analysis showed a significantly higher cumulative probability of live birth in patients <36 versus >36 in EFP (P < 0.0001), with improved outcomes when more oocytes were available for IVF. LIMITATIONS, REASONS FOR CAUTION: Statistical power to compare IVF outcomes is limited by the few women who came to use their oocytes in the Onco-FP group. The patients' ages and the COS protocols used were significantly different between the EFP and ONCO-PP groups. WIDER IMPLICATIONS OF THE FINDINGS: Although the implantation rate was significantly lower in the Onco-FP patients the impact of cancer disease per se was not proven'. EFP patients should be counseled according to their age and number of available oocytes. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly efficient vitrification for cryopreservation of human oocytes and embryos: The Cryotop method
Kuwayama, M. (2007) · Theriogenology · doi:10.1016/j.theriogenology.2006.09.014 · Cited by 855
Rienzi, L., Gracia, C., Maggiulli, R., LaBarbera, A. R., Kaser, D. J., Ubaldi, F. M., Vanderpoel, S., & Racowsky, C. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw038 · Cited by 729
Oocyte vitrification as an efficient option for elective fertility preservation
Cobo, A., García-Velasco, J. A., Coello, A., Domingo, J., Pellicer, A., & Remohí, J. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.11.027 · Cited by 536
Self-citationOktay, K., Hourvitz, A., Sahin, G., Oktem, O., Safro, B., Cil, A., & Bang, H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0962 · Cited by 421
Green, D. M., Whitton, J. A., Stovall, M., Mertens, A. C., Donaldson, S. S., Ruymann, F. B., Pendergrass, T. W., & Robison, L. L. (2002) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2002.126643 · Cited by 372
Oktay, K., Kim, J. Y., Barad, D., & Babayev, S. N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2057 · Cited by 355
Doyle, J. O., Richter, K. S., Lim, J., Stillman, R. J., Graham, J. R., & Tucker, M. J. (2016) · Fertility and Sterility · doi:10.1016/j.fertnstert.2015.10.026 · Cited by 305
Niederberger, C., Pellicer, A., Cohen, J., Gardner, D. K., Palermo, G. D., O’Neill, C. L., Chow, S., Rosenwaks, Z., Cobo, A., Swain, J. E., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.06.005 · Cited by 301
Self-citationOocyte cryopreservation: where are we now?
Argyle, C. E., Harper, J. C., & Davies, M. C. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw007 · Cited by 291
Hodes-Wertz, B., Druckenmiller, S., Smith, M., & Noyes, N. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.07.201 · Cited by 270
Cited by
Rethinking mechanisms, diagnosis and management of endometriosis
Chapron, C., Marcellin, L., Borghese, B., & Santulli, P. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0245-z · Cited by 1,084
(2019) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.09.013 · Cited by 753
ESHRE guideline: female fertility preservation
The ESHRE Guideline Group on Female Fertility Preservation, Anderson, R. A., Amant, F., Braat, D., D'Angelo, A., Chuva de Sousa Lopes, S. M., Demeestere, I., Dwek, S., Frith, L., Lambertini, M., et al. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoaa052 · Cited by 748
Oocyte vitrification for fertility preservation for both medical and nonmedical reasons
Cobo, A., García-Velasco, J. A., Remohí, J., & Pellicer, A. (2021) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.02.006 · Cited by 165
Self-citationOocyte vitrification for fertility preservation in women with endometriosis: an observational study
Cobo, A., Giles, J., Paolelli, S., Pellicer, A., Remohí, J., & García-Velasco, J. A. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2019.11.017 · Cited by 127
Self-citation
Metadata
- Authors
- Cobo, A., García-Velasco, J., Domingo, J., Pellicer, A., & Remohí, J.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-10-31
- Volume
- 33
- Issue
- 12
- Pages
- 2222-2231
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2904754806
- Cited by
- 364
- References
- 41
- FWCI
- 26.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elective and Onco-fertility preservation: factors related to IVF outcomes. https://app.cochat.ai/papers/10.1093/humrep/dey321
- The paper
- Cobo, A., García-Velasco, J., Domingo, J., Pellicer, A., & Remohí, J. (2018). Elective and Onco-fertility preservation: factors related to IVF outcomes. Human Reproduction. https://doi.org/10.1093/humrep/dey321
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.